Latest news

  • 07 November 2019

    Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover. Read

  • 31 October 2019

    Sensorion reports its 2019 first half results - Signature of a framework agreement with Institut Pasteur in gene therapy - Financial position strengthened with the issuance of a €20m mandatory convertible bond. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more